Celularity (CELU) Cash from Financing Activities (2019 - 2025)
Celularity (CELU) posted quarterly Cash from Financing Activities of $11.2 million for Q4 2025, up 1644.95% year-over-year from $643000.0 in Q4 2024, and up 222.6% quarter-over-quarter from $3.5 million in Q3 2025.
Celularity (CELU) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Cash from Financing Activities for 7 consecutive years, with $11.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 1644.95% year-over-year to $11.2 million; the TTM figure through Dec 2025 stood at $18.6 million (up 178.3% YoY), while the FY2025 annual figure was $18.6 million, up 178.3% from the prior year.
- Cash from Financing Activities rose to $11.2 million in Q4 2025 per CELU's latest filing, from $3.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $100.4 million in Q3 2021 and bottomed at -$4.8 million in Q1 2021.
- Historically, Cash from Financing Activities has averaged $13.4 million across 5 years, with a median of $3.7 million in 2021.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities tumbled 219.87% — and 2024, when it surged 4692.86%.
- Celularity's Cash from Financing Activities stood at -$1.0 million in 2021, then jumped by 266.17% to $1.7 million in 2022, then slumped by 100.83% to -$14000.0 in 2023, then soared by 4692.86% to $643000.0 in 2024, then jumped by 1644.95% to $11.2 million in 2025.
- Business Quant data shows CELU's Cash from Financing Activities at $11.2 million in Q4 2025, $3.5 million in Q3 2025, and $1.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | 11.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.22 Mn |
| Dec 31, 2025 | 11.22 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 1.63 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 643,000.00 |
| Dec 31, 2024 | 643,000.00 |
| Sep 30, 2024 | -79,000.00 |
| Sep 30, 2024 | -79,000.00 |
| Jun 30, 2024 | -90,000.00 |
| Jun 30, 2024 | -90,000.00 |
| Mar 31, 2024 | 6.23 Mn |
| Mar 31, 2024 | 6.23 Mn |
| Dec 31, 2023 | -14,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Sep 30, 2023 | 5.74 Mn |
| Sep 30, 2023 | 5.74 Mn |